Page Banner

United States Department of Agriculture

Agricultural Research Service

Title: The Effect of Granulocyte-Macrophage Colony-Stimulating Factor on the Efficacy of a Foot-and-Mouth Disease Virus Subunit Vaccine

Authors
item Caron, Luizinho - USDA, ARS, NAA, PIADC
item Brum, Mario - USDA, ARS, NAA, PIADC
item Moraes, Mauro - FED UNIV VICOSA, BRAZIL
item Golde, William
item Weis Arns, Clarice - LAB VIROLOGIA CAMPINAS BZ
item Grubman, Marvin

Submitted to: Pesquisa Veterinaria Brasileira
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: November 4, 2004
Publication Date: N/A

Technical Abstract: Foot-and-mouth disease (FMD) is one of the most feared diseases of livestock worldwide. Vaccination has been a very effective weapon in controlling the disease, however a number of concerns with the current vaccine including the need for high containment facilities for vaccine production, the inaccuracy of approved tests to distinguish vaccinated from infected animals, have limited its use during outbreaks in countries previously free of the disease. A number of FMD vaccine candidates have been tested and a replication-defective human adenovirus type 5 (Ad5) vector containing the FMDV capsid (P1-2A) and 3C protease coding regions has been shown to completely protect pigs against the homologous virus (FMDV A12 and A24). An Ad5-P1-2A+3C vaccine for FMDV 01 Campos (Ad5-01C), however, only induced a low FMDV-specific neutralizing antibody response in swine potency tests. To improve the FMDV-specific immune response induced by Ad5-01C, we inoculated swine with Ad5-01C and an Ad5 vector containing the gene for porcine granulocyte-macrophage colony-stimulating factor (pGM-CSF). GM-CSF has been successfully used to stimulate the immune response in vaccine formulations against a number of diseases, including HIV, hepatitis B and C, etc. However, in the conditions used in this trail, GM-CSF did not improve the immune response to Ad5-01C or enhance the protection of swine challenged with homologous FMDV.

Last Modified: 4/20/2014
Footer Content Back to Top of Page